




## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07D 305/14, A61K 31/335, C07F 7/18, C07C 271/18</b>		<b>A1</b>	(11) International Publication Number: <b>WO 97/07110</b>
			(43) International Publication Date: 27 February 1997 (27.02.97)
(21) International Application Number: <b>PCT/US96/12666</b>			<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 2 August 1996 (02.08.96)			
<b>(30) Priority Data:</b> 60/002,140 11 August 1995 (11.08.95) US 08/589,142 19 January 1996 (19.01.96) US			
(71) Applicant: SEPRACOR, INC. [US/US]; 111 Locke Drive, Marlborough, MA 01752 (US).			
<b>(72) Inventors:</b> GAO, Yun; 7 Davis Road, Southborough, MA 01772 (US). ZEPP, Charles, M.; 940 North Road, Hardwick, MA 01047 (US).  <b>(74) Agents:</b> HANSEN, Philip, E. et al.; Heslin & Rothenberg, P.C., 5 Columbia Circle, Albany, NY 12205 (US).			

**Published***With international search report.**Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.***(54) Title:** PROCESS FOR PRODUCING TAXOL DERIVATIVES AND INTERMEDIATES THEREFOR**(57) Abstract**

A process for the preparation of taxol and derivatives of taxol (I) is disclosed. The process involves reacting a  $\beta$ -alkoxycarbonylamino-phenylpropionic acid with a 13-hydroxy taxane to produce an ester of the taxane at C-13; and then deprotecting the  $\beta$ -alkoxycarbonylamino-phenylpropionic ester to produce a  $\beta$ -amino- $\alpha$ -hydroxybenzenepropanoic ester of the taxane. Intermediates useful in the process are also disclosed.

**(I)**

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

-1-

# PROCESS FOR PRODUCING TAXOL DERIVATIVES AND INTERMEDIATES THEREFOR

## Field of the Invention

The invention relates to a process for the preparation of taxol I and derivatives of taxol



5

# I

and to intermediates useful in the process.


## Background of the Invention

Taxol (I) is currently in clinical trials and has demonstrated efficacy with manageable side effects in 30 to 35% of cases of ovarian cancer and 56% of cases of metastatic breast cancer, but large scale clinical trials have been hampered by the small available supplies of the drug.

Taxol, whose generic name as a drug is  
15 paclitaxel, is currently produced by extraction from  
the bark of the Pacific yew, *Taxus brevifolia*. The  
Pacific yew is a slow growing conifer found in the

-2-

understory of old growth stands in the Pacific Northwest. Ten thousand kilograms of bark are required to produce one kilogram of taxol, which is enough to treat only 500 patients. For this reason  
5 the chemical synthesis of taxol has aroused great interest. However, the sterically crowded, chemically sensitive and chirally complex taxane ring structure




II

10 has essentially forestalled any practical synthesis *de novo*. As a result, current chemical efforts are focused on semisynthesis from more readily available congeners. The chemistry of taxol and related diterpenoids has been described in two excellent  
15 recent review articles [Kingston, Pharm. Ther. 52, 1-34 (1991) and Nicolaou et al. Angew. Chem. Int. Ed. 33, 15-44 (1994)].


Although no good source of taxol has been found, a related compound baccatin III,

-3-



III

wherein R is hydrogen, is much more readily available from the needles of the European yew, *Taxus baccata*. This has led to a very active exploration of semi-synthetic routes from baccatin to taxol. The most practical present routes of semi-synthesis involve the attachment of the side chain of taxol.




IV

onto a suitably protected baccatin, followed by deprotection.


Several of the known routes for the semi-synthesis of taxol proceed through a substantially optically pure azido ester of the formula V:

- 4 -




V

The azide is reduced, resulting in a trans-acylation from oxygen to nitrogen;



VI


5 the hydroxyl of the resulting  $\beta$ -amido ester VII



VII

is protected; and the ester is saponified to produce the protected carboxylic acid VIII:

-5-



VIII


This protected acid is then coupled with the suitably protected taxane ring system. Consistent with common usage, the term "taxane" is understood to encompass  
5 diterpenoids having a 6,10-methanobenzocyclodecane ring structure oxygenated at least at the 3,5,8,11 and 12 positions and carbon-substituted at 4,6,9,12a,13 and 13. In the case of taxanes of present therapeutic interest (having the baccatin and  
10 taxol ring structures), the oxygen at position 8 of the methanobenzocyclodecane is an alcohol (which will be esterified) and the carbon at 4 and the oxygen at 3 are cyclized to form an oxetane ring. Structure II above reflects the pattern of substitution of the  
15 taxanes of interest and shows the numbering system commonly used for taxol, which is different from the numbering system of the parent methanobenzocyclodecane.

#### Summary of the Invention

20 The process of the invention shown in Scheme A provides an improved synthesis of taxol and related structures by the coupling of an optically pure  $\beta$ -protected amino carboxylic acid (IX) with the  
suitably protected taxane ring structure X in which  $R^2$   
25 is a protecting group for an alcohol (see below):

-6-

Scheme A




The amino protecting group is then removed to  
 liberate the free amine, which undergoes internal  
 transacylation to produce the desired  $\alpha$ -hydroxyl  $\beta$ -  
 5 amido sidechain in the taxol.

In one aspect, the invention relates to a  
 process for the preparation of taxol, and derivatives  
 thereof, comprising: (a) reacting a  $\beta$ -alkoxycarbonyl-  
 aminophenylpropionic acid of formula (XII) wherein R<sup>1</sup>  
 is C<sub>1</sub> to C<sub>10</sub> alkyl, phenyl or substituted phenyl; R<sup>3</sup>  
 10 is hydrogen, loweralkyl, loweralkoxyl, di-



-7-

loweralkylamino or halo; and R<sup>4</sup> is benzyl (Cbz), t-butyl (tBoc), allyl (Aloc), trichloroethyl (Troc), or 9-fluorenylmethyl (Fmoc), with a 13-hydroxy taxane to produce an amidophenylpropionic ester at C-13 of the taxane;




XII

and (b) removing the  $\beta$ -amino protecting group by treatment with an acid or by reduction followed by internal acyl transfer to produce a  $\beta$ -amido- $\alpha$ -hydroxyphenylpropionic ester of the taxane. Preferred R<sup>1</sup> substituents are phenyl, substituted phenyl (particularly 4-chlorophenyl) or t-butoxyl; the preferred R<sup>3</sup> is hydrogen. The term "alkyl" as used herein refers to saturated hydrocarbons, including straight and branched chains as well as cyclic structures such as cyclohexyl. Lower alkyl refers to alkyl of six or fewer carbons. The definitions of substituents are presented herein in their first occurrence and retain that definition throughout the text.


In a more specific embodiment, the process of the invention relates to a process as above comprising (a) reacting a  $\beta$ -alkoxycarbonylamino-phenylpropionic acid of formula (IX), wherein R<sup>4</sup> is t-butyl, benzyl or 9-fluorenylmethyl,

-8-



IX


with a taxane of formula (X)



X


-9-

to produce an alkoxycarbonylaminophenylpropionic ester at C-13 of formula (XI)



XI

and (b) removing the alkoxycarbonyl protecting group  
5 of the phenylpropionic ester of taxane to produce a  
β-amido-α-hydroxyphenylpropionic ester of taxane of  
formula XIII:



XIII


10 wherein R<sup>2</sup> is a protecting group for an alcohol. The  
term "protecting group for an alcohol" refers to a  
residue that is stable under the conditions of the

-10-

condensation of the benzenepropanoic acid with the 13-hydroxy taxane, but that can be cleaved to an alcohol under conditions that do not otherwise affect the  $\beta$ -amido- $\alpha$ -hydroxybenzenepropanoic ester of the taxane. Suitable protecting groups include 1,1,1-trichloroethoxycarbonyl (Troc), removable by zinc in acetic acid and aryldialkylsilanes or trialkylsilanes, removable by mild acid such as 0.5% HCl in methanol. A preferred protecting group for the C-7 hydroxyl is trihexylsilyl.

The process of the invention may further comprise the additional step of cleaving the protecting group  $R^2$  to produce taxol, and the step of deprotecting the  $\beta$ -aminobenzenepropanoic ester may also cleave the protecting group  $R^2$ , whereby a 2',7-dihydroxy-3'-amidoester is produced in a single reaction.

In a further aspect, the invention relates to compounds of formula XIV:




XIV

wherein  $R^1$  is  $\text{C}_1$  to  $\text{C}_{10}$  alkyl,  $\text{C}_1$  to  $\text{C}_{10}$  alkoxy, phenyl or substituted phenyl;  $R^3$  is hydrogen, loweralkyl, loweralkoxy, di-loweralkylamino or halo and  $R^4$  is allyl, benzyl, t-butyl, or 9-fluorenylmethyl. The

-11-

compounds are novel and are useful for preparing taxol according to the method of the invention. Preferred compounds are those in which  $R^1$  is phenyl, t-butoxyl or 4-chlorophenyl and  $R^3$  is hydrogen.

5 In a further embodiment, the invention relates to compounds of formula XV



XV

wherein  $R^2$  is trialkylsilyl (e.g. t-butyltrimethylsilyl, trihexylsilyl, triethylsilyl or  
 10 trimethylsilyl), or aryldialkylsilyl (e.g. phenyldimethylsilyl) and the other substituents are as defined before. The compounds are useful as intermediates in the process of the invention.

#### Detailed Description of the Invention


15 The central process of the invention involves the reaction of a suitably protected 13-hydroxy-taxane X with a  $\beta$ -alkoxycarbonylamino-phenylpropionic acid XIV to form the ester XV. In a second step the amine is deprotected by procedures known in the art,  
 20 such as hydrogenation in the presence of a catalyst

-12-

(for  $R^4$  = benzyl) or treatment with mild acid (for  $R^4$  = t-butyl), whereupon the acyl group is transferred from the  $\alpha$ -oxygen to the newly created  $\beta$ -amino function. The C-7 hydroxyl of baccatin is the most  
5 reactive hydroxyl and must commonly be protected during the reaction to form the ester. It will then be deprotected in a final step to produce taxol or a taxol analog. The reaction is shown below in Scheme B, which is a generic version of Scheme A:

-13-

SCHEME B




-14-

The process of the invention is distinguished from processes of the art (shown in Scheme C) in which an  $\alpha$ -hydroxyl-protected  $\beta$ -amidobenzenepropanoic acid XVII



-15-


## SCHEME C



-16-

is reacted with the suitably protected taxane X and the protecting group R<sup>4</sup> is subsequently removed from the  $\alpha$ -hydroxyl.


The optically pure  $\beta$ -alkoxycarbonylamino-phenyl-  
5 propionic acid XIV



XIV

may be prepared by a number of possible routes. In one synthetic route (Scheme D),

SCHEME D




10 readily available optically pure (2R, 3S)-  
phenylisoserine is treated with an alkyl  
chloroformate or equivalent such as di-*t*-butyl  
dicarbonate [(Boc)<sub>2</sub>O] under Schotten-Baumann  
conditions (aq. NaOH or K<sub>2</sub>CO<sub>3</sub>) to give the  $\beta$ -  
15 alkoxy-carbonylamino- $\alpha$ -hydroxyl acid. The  $\alpha$ -hydroxyl  
of the acid is then reacted with an acid chloride  
such as benzoyl chloride in the presence of a base  
such as aqueous NaOH to give the desired  $\beta$ -  
alkoxy-carbonylamino-phenylpropionic acid after  
20 neutralization and purification.

-17-

Alternatively, as shown in Scheme E, the  $\beta$ -alkoxycarbonyl-aminophenylpropionic acid can be synthesized from optically pure ethyl (2R,3S)-phenylglycidate, which is obtained by enzymatic resolution of the racemic glycidate according to the method of U.S. patent 5,274,300 or from ethyl (2R,3S)-2,3-dihydroxy-3-phenylpropionate according to the procedure of Kolb et al [Tetrahedron 48, 10515 (1992)]. The ethyl (2R,3S)-phenylglycidate is then converted to the trimethylsilylethyl ester by treatment with 2-trimethylsilylethanol in the presence of a base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU). The resulting epoxide is opened with a source of  $\text{Br}^-$ , such as lithium bromide in acetic acid/THF or diethylamine hydrobromide, in the presence of an aluminum compound, such as diethylaluminum chloride, to produce (2R,3R)-3-bromo-2-hydroxy-3-phenylpropionate XXIII, which is then treated with sodium azide in DMF to produce the  $\beta$ -azidopropionate. The 3-azido-2-hydroxy ester is then reduced to the  $\beta$ -amino ester which is then treated with an alkyl chloroformate ( $\text{R}^4\text{OCOCl}$ ) followed by an acid chloride ( $\text{R}^1\text{COCl}$ ), such as benzoyl chloride, to produce the appropriate 3-alkoxycarbonylamino-2-acyloxyphenylpropionate ester.

-18-

## SCHEME E



Alternatively, the 3-azido-2-hydroxy ester is treated with an acid chloride ( $R^1COCl$ ), such as benzoyl chloride, to give the 3-azido-2-acyloxy ester which is then hydrogenated in the presence of di-alkyl-dicarbonate, such as  $Boc_2O$ , under 1 atm of hydrogen

-19-

over a catalyst, such as Pd/C, to give the 3-alkoxycarbonylamino-2-acyloxyphenylpropionic ester. The trimethylsilylethyl ester is then treated with tetrabutylammonium fluoride in THF to give the 3-alkoxycarbonylamino-2-acyloxyphenylpropionic acid after acidification.

Alternative syntheses of various of the intermediates in the synthesis of the  $\beta$ -azido benzenepropanoic acid have been published by Gou et al. [J. Org. Chem. **58**, 1287-1289 (1993)], Bajwa et al. [Tetrahedron Letters **32**, 3021-3024 (1991)] and Bonini et al. [J. Chem. Soc. Chem. Commun. (1994) 2767-2768], and the reader is directed to those references for details.

The condensation of the  $\beta$ -alkoxycarbonyl-aminophenylpropionic acid with a suitably protected baccatin can be carried out using standard ester formation methods. Preferably, the condensation of the baccatin with the acid sidechain is performed using at least one equivalent of the acid in the presence of at least one equivalent of activating reagent such as dialkylcarbodiimide, di-2-pyridylcarbonate and PhOPCl<sub>2</sub> or Me<sub>2</sub>NPOCl<sub>2</sub> and a base such as 4-dimethylaminopyridine (DMAP) or 4-pyrrolidinopyridine (4-PP) in an inert solvent. Most preferably, the condensation is performed using 1.2-1.5 equivalents of the acid XIV in the presence of 1.2-1.5 equivalents of DCC or DIC and 0.2-0.5 equivalents of DMAP or 4-PP in toluene at 40-50°C for 4-10 hours.

-20-

When R<sup>4</sup> of the alkoxycarbonylaminophenylpropionic acid is t-butyl and R<sup>2</sup> of the 7-hydroxyl protecting group is a silyl group, the conversion of the condensation product to taxol and analogs is most conveniently accomplished in acidic medium such as trifluoroacetic acid (TFA) in methylene dichloride or THF or in neat formic acid. When R<sup>4</sup> is benzyl, allyl, or 9-fluorenylmethyl and R<sup>2</sup> is silyl, the conversion is accomplished by removal of the silyl group with an acid, as above, or with HF/pyridine or with tetrabutylammonium fluoride in THF followed by catalytic hydrogenation using Pd/C or Pd(PPh<sub>3</sub>)<sub>4</sub> and hydrogen or a hydrogen donor such as ammonium formate.

When R<sup>4</sup> is trichloroethyl and R<sup>2</sup> is trichloroethoxycarbonyl, the conversion is accomplished by reduction with zinc in HOAc. Under these conditions, the taxol is recovered by neutralization with an aqueous solution of sodium bicarbonate in an inert solvent such as ethyl acetate, toluene or methylene dichloride, followed by purification by crystallization or chromatography on silica gel.

Several possible alcohol protecting groups R<sup>2</sup> for the C-7 hydroxyl were compared as to ease of protection and deprotection, stability of the product towards further reaction conditions, selectivity of the reaction for the protection of the desired functional group over other hydroxyl groups in the molecule, ease of purification and cost of the materials. As a part of the exploration of R<sup>2</sup> groups, the acetylation of the C-10 hydroxyl group was also

-21-

studied, and the results of this study are presented in the experimental section below.

10-Deacetyl baccatin-III (10-DAB) was treated with a variety of reagents under a number of reaction conditions. It appears that silyl protecting groups were more well behaved than other common protecting groups. Treatment of 10-DAB with triethylsilyl chloride and imidazole in DMF resulted in the smooth preparation of the triethyl silyl ether in 70% yield. Under similar conditions, treatment with t-butylmethoxyphenylsilyl bromide resulted in the silylated taxoid in a yield of 89%. The phenyldimethyl silyl derivative was prepared in an acceptable yield of 74%.

A preferred protecting group is tri-n-hexylsilyl. When treated with tri-n-hexylsilyl chloride, 10-DAB underwent smooth silylation to produce the C-7 silylated material in 80% yield. Very importantly, the pure tri-n-hexylsilyl ether product is obtained by recrystallization. No chromatography is necessary.

Acetylation at C-10 of the C-7 silylated substrates was accomplished by treatment with acetyl chloride in pyridine at 0°C. Acetylation of both the triethylsilyl and tri-n-hexylsilyl ethers proceeded to give the desired acylation at the C-10 hydroxyl group. Although in both cases some desilylation occurred, it is postulated that this side reaction, which is probably induced by hydrochloric acid generated during the reaction, may be suppressed by modification of the existing conditions or by acylation of the discrete alkoxide. The more labile

-22-

phenyldimethylsilyl group is cleaved to a greater extent than the trialkylsilyl ethers under the same reaction conditions. The unoptimized yield for the acylation of the tri-n-hexylsilyl derivative is 70%.

5           The removal of the C-7 silyl protecting group may be accomplished by HF in pyridine, resulting in clean conversion to the free alcohol. Cleavage of the tri-n-hexylsilyl ether was slower than the triethylsilyl ether; the yield for the tri-n-  
10 hexylsilyl ether deprotection was 68%. In the case of the 7-TES derivative, HF in acetonitrile proved too harsh and resulted in the production of a complex mixture of products.

          The presently preferred candidate for C-7  
15 hydroxyl protection is the tri-n-hexylsilyl ether. Tri-n-hexylsilyl chloride has similar reactivity to triethylsilyl chloride and is cheaper than triethylsilyl chloride; the intermediate ether can be purified by recrystallization; and the protecting  
20 group can be cleanly cleaved.

          Although the synthesis has been illustrated with compounds in which  $R^1$  is phenyl and  $R^3$  is hydrogen, the person of skill will readily appreciate that analogous reactions could be carried out employing  
25 starting materials and intermediates in which  $R^1$  is other than phenyl and  $R^3$  is other than hydrogen.



**Examples:****Example-1:**

(2R,3S)-phenylisoserine hydrochloride (6.0 g, 27.6 mmol) was dissolved in H<sub>2</sub>O/tBuOH (50 mL each) at room temperature. A solution of NaOH (50% aq., 4.6 g, 58 mmol) was added followed by di-t-butyl dicarbonate (7.23 g, 33.1 mmol). The resulting mixture was stirred at room temperature overnight and concentrated to ca. 30 mL. The residue was diluted with EtOAc (150 mL) and acidified with 1 N H<sub>2</sub>SO<sub>4</sub> to pH 3-4. The aq. phase was separated and extracted with 50 mL of ethyl acetate (EtOAc). The combined organic phase was washed with sat'd NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. After filtration and concentration, the resulting yellow solid was recrystallized from EtOAc/heptane to give (2R,3S)-3-t-butyloxycarbonylamino-2-hydroxyphenylpropionic acid as a white solid (5.9 g, 75.6% yield).

**Example-2:**

(2R,3S)-3-t-butyloxycarbonylamino-2-hydroxyphenylpropionic acid (1.41 g, 5 mmol) was dissolved in H<sub>2</sub>O/acetone (10 mL each) containing 0.4 g of 50% aq. NaOH (5 mmol). The solution was cooled with ice water. Benzoyl chloride (1.2 mL, 10 mmol) and 1 N NaOH solution were added alternatively in small portions while maintaining the pH at ca. 10-11. After addition, the mixture was stirred at room temperature for 2 h at pH 9-11. The mixture was then diluted with EtOAc (100 mL) and acidified with 1 N H<sub>2</sub>SO<sub>4</sub> to pH 2-3. The aq. phase was separated and extracted with 30 mL of EtOAc. The combined organic phase was washed with sat'd NaCl and dried over Na<sub>2</sub>SO<sub>4</sub>. The crude product was then purified on silica gel eluting with

-24-

EtOAc/hexane and EtOAc to give (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid as a white solid (0.96 g, 50 % yield).

**Example-3:**

5 Ethyl (2R,3S)-phenylglycidate (36 g, 0.19 mol) was treated with 2-trimethylsilylethanol (67 g, 0.57 mol) in toluene (100 mL) in the presence of catalytic amount of DBU at 60-80 C for 2-3 days. The reaction was then concentrated under vacuum to give the crude  
10 trimethylsilyl ethyl ester (ca. 50 g). The crude ester was dissolved in THF (150 mL) and cooled with icewater. Acetic acid (44 mL, 0.8 mol) was added followed by LiBr (49 g, 0.56 mol) in three portions. The mixture was stirred from 5 C to room temperature  
15 for 26 h and was concentrated to dryness to remove THF. The residue was diluted with 100 mL of H<sub>2</sub>O and extracted with 2x300 mL of methyl t-butyl ether (MTBE). The MTBE extracts were then washed with water (50 mL) and sat'd NaCl and concentrated to give a  
20 crude oil which was purified on silica gel eluting with hexane and 10% EtOAc in hexane to give a white solid (12.4 g, 19% yield) as the (2R,3R)-3-bromo-2-hydroxyphenylpropionic acid 2-trimethylsilylethyl ester.

**Example-4:**

25 The ester from Example-3 (12.3 g, 35.6 mmol) was treated with NaN<sub>3</sub> (7.0 g, 0.11 mol) in 40 mL of DMF at 60-70 C for 18 h. The mixture was cooled and diluted with 50 mL of water and extracted with 300 mL of  
30 MTBE. The MTBE solution was washed with water (40 mL) and sat'd NaCl (30 mL) and concentrated to give a crude oil which was purified on silica gel eluting with hexane and 10% EtOAc/hexane to give (2R,3S)-3-

-25-

azido-2-hydroxyphenylpropionic acid 2-trimethylsilyl-ethyl ester (11.0 g, 100% yield).

**Example-5:**

The azido ester from Example-4 (11.0 g, 35.6 mmol) was hydrogenated on a Parr-shaker at 50 psi in ethanol (EtOH) in the presence of catalytic amount of Pd/C (2.0 g). After removal of the catalyst and concentration, the resulting 3-amino-2-hydroxyphenylpropionic ester was dissolved in tetrahydrofuran (THF) (50 mL) and treated with di-*t*-butyl dicarbonate (9.3 g, 42.7 mmol) and Et<sub>3</sub>N (7.2 g, 71.2 mmol) at room temperature overnight. The mixture was concentrated and diluted with MTBE (250 mL) and washed with water and brine. After drying and concentration, the residue was purified on silica gel eluting with hexane and 10% EtOAc/hexane to give (2*R*,3*S*)-3-*t*-butyloxycarbonylamino-2-hydroxyphenylpropionic acid 2-trimethylsilylethyl ester (12.0 g, 90% yield).

**Example-6:**

The ester (12 g, 31.5 mmol) from example-5 was dissolved in THF (50 mL) and cooled with icewater. Et<sub>3</sub>N (6.4 g, 63 mmol) was added, followed by benzoyl chloride (5.3 g, 38 mmol) dropwise with cooling. The resulting mixture was stirred at room temperature overnight and diluted with EtOAc (250 mL) and quenched with 50 mL of water. The aq. phase was separated and the organic phase was washed with dilute H<sub>2</sub>SO<sub>4</sub>, water and then sat'd aq. NaHCO<sub>3</sub>. After drying, the crude product was purified on silica gel eluting with hexane and 10% EtOAc/hexane to give (2*R*,3*S*)-3-*t*-butyloxycarbonylamino-2-

-26-

benzoyloxyphenylpropionic acid 2-trimethylsilylethyl ester (13.8 g, 90% yield).

**Example-7:**

The ester (13.8 g, 28.4 mmol) from Example-6 was dissolved in THF (50 mL) and cooled with icewater. Tetrabutylammonium fluoride in THF (1.0 M in THF, 57 mL) was added dropwise. The resulting solution was stirred at room temperature for 7 h and concentrated to dryness. The residue was dissolved in 300 mL of EtOAc and acidified with 1 N H<sub>2</sub>SO<sub>4</sub> to pH 3-4. The EtOAc solution was then washed with water (20 mL) and sat'd NaCl (20 mL) and concentrated to dryness. The crude product was purified on silica gel eluting with EtOAc to give (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid as a white solid (8.7 g, 80% yield).

**Example-8:**

The 3-azido-2-hydroxy ester from Example-4 (11.0 g, 35.6 mmol) was dissolved in 100 mL of EtOAc and 50 mL of THF. Triethylamine (10 mL, 71.2 mmol) was added and the solution was cooled with icewater. Benzoyl chloride (4.2 mL, 36 mmol) was added and the mixture was stirred at room temperature for 20 h. The mixture was quenched with 50 mL of water and diluted with 150 mL of EtOAc. The organic phase was separated and washed with dilute H<sub>2</sub>SO<sub>4</sub>, water and sat'd NaCl and concentrated. The residue was then purified on silica gel eluting with hexane and 7% EtOAc/hexane to give 3-azido-2-benzoyloxyphenylpropionic acid 2-trimethylsilylethyl ester as a pale yellow oil (10.6 g, 72% yield).

-27-

**Example-9:**

The 3-azido-2-benzoyloxy ester from Example-8 (2.06 g, 5 mmol) was dissolved in EtOAc (20 mL) and di-t-butyl-dicarbonate (2.2 g, 10 mmol) and 0.2 g of 10% Pd/C were added. The mixture was hydrogenated at 1 atm with stirring at room temperature for 4 days and then filtered. The filtrate was concentrated to give a residue which was purified on silica gel eluting with hexane and 10% EtOAc/hexane to give 3-t-butylloxycarbonylamino-2-benzoyloxyphenylpropionic acid 2-trimethylsilylethyl ester as a glassy solid (2.0 g, 84% yield).

**Example-10:**

The ester from Example-9 (2.0 g, 4.22 mmol) was dissolved in 20 mL of THF and  $n\text{Bu}_4\text{NF}$  in THF (1.0 M, 8.5 mL, 8.5 mmol) was added. The solution was stirred at room temperature for 3 h and concentrated to dryness. The residue was dissolved in EtOAc (150 mL) and acidified with dilute  $\text{H}_2\text{SO}_4$  to pH 3-4. The organic phase was then washed with sat'd NaCl and concentrated. The residue was purified on silica gel eluting with EtOAc to give a white solid as (2R,3S)-3-t-butylloxycarbonylamino-2-benzoyloxyphenylpropionic acid (1.28g, 78.5% yield).

**Example-11:**

10-Deacetylbaecatin III (1 g, 1.8 mmol) and imidazole, (980 mg, 14.4 mmol) were dissolved in 60 mL dry DMF under an atmosphere of argon in a 200 mL roundbottom flask equipped with a stirring bar. Tri-n-hexylsilyl chloride (4 mL, 10.8 mmol) was added and the mixture was stirred for 6 h at room temperature. Ethyl acetate and water were added and the phases

-28-

allowed to separate. The organic layer was separated and the aqueous phase was washed with brine and dried over anhydrous  $\text{MgSO}_4$ . After filtration and evaporation of the solvent under reduced pressure, the crude product was recrystallized from methylene chloride and hexanes to yield 1.11g of the pure product (74% yield): mp. 203°C.

**Example-12.**

7-Tri-n-hexylsilyl-10-deacetylbaecatin III (250 mg. 0.3 mmol) from example 11 was dissolved in 7.7 mL of anhydrous pyridine under an argon atmosphere in a 25 mL roundbottom flask equipped with a stirring bar. The solution was cooled to 0°C and acetyl chloride (100  $\mu\text{L}$ , 1.5 mmol) was added dropwise. The mixture was stirred for 20 h at 0°C. A further 100  $\mu\text{L}$  of acetyl chloride was added and the mixture stirred for another 20 h at 0°C. Ethyl acetate was added, followed by water at 0°C. The organic phase was removed and the aqueous phase was extracted twice with ethyl acetate. The organic layers were combined and washed with saturated  $\text{CuSO}_4$  solution, (until the pyridine had been completely removed), water and brine and finally dried over anhydrous  $\text{MgSO}_4$ . After filtration, and removal of the solvent under reduced pressure, the resulting residue was purified by flash chromatography on silica gel (elution with 30-50% ethyl acetate/hexanes) to yield 171 mg of pure product (66% yield).

**Example-13**

7-Tri-n-hexylsilylbaecatin III (250 mg, 0.3 mmol) from example 12 was dissolved in 15 mL of anhydrous THF under an atmosphere of argon in a 50 mL round-bottom flask equipped with a stirring bar. HF-

-29-

pyridine (3 mL) was then added dropwise. The reaction mixture was stirred for 2 h at 25°C. Ethyl acetate and water were added. After separation of the phases, the aqueous phase was extracted twice  
5 with ethyl acetate. The combined organic extracts were washed with saturated copper sulphate, water and brine, and dried over anhydrous magnesium sulphate. After filtration and removal of the solvent under reduced pressure, the residue was purified by flash  
10 chromatography on silica gel (elution with 70-100% ethyl acetate/hexanes) to yield 111 mg of pure baccatin III (68% yield).

**Example-14**

A mixture of (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid (78 mg, 0.2 mmol)  
15 (Example 10), dicyclohexylcarbodiimide (DCC) (41 mg, 0.2 mmol), 4-pyrrolidinopyridine (15 mg, 0.1 mmol) and 7- triethylsilyl baccatin (TES-baccatin) (70 mg, 0.1 mmol) in 0.3 mL of dry toluene was heated at 50 C  
20 for 6 h. The mixture was then concentrated and purified on silica gel eluting with hexane and 30% EtOAc/hexane to give the (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid ester of 7-TES-baccatin at the C-13 hydroxyl  
25 group as a white solid (100 mg, 93% yield).

**Example-15:**

A mixture of (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid (78 mg, 0.2 mmol),  
diisopropylcarbodiimide (DIC) (38 mg, 0.3 mmol), 4-  
30 pyrrolidinopyridine (15 mg, 0.1 mmol) and 7-TES-baccatin (94mg, 0.134 mmol) in 0.5 mL of dry toluene was heated at 50 C for 6.5 h. The solution was then cooled and diluted with EtOAc/toluene and washed with

-30-

water, dilute  $\text{H}_2\text{SO}_4$  and sat'd  $\text{NaCl}$ . The solution was concentrated to dryness to give crude (2R,3S)-3-t-butyloxycarbonylamino-2-benzoyloxyphenylpropionic acid ester of 7-TES-baccatin (200 mg).

**Example-16:**

As an alternative to example 5, the (2R,3S)-3-azido-2-hydroxyphenylpropionic acid, 2-trimethylsilylethyl ester from Example-4 (6.2 g, 20.2 mmol) was treated with ammonium formate (5 g, 80 mmol) in the presence of 10% Pd/C (0.6 g) in 50 mL of methanol for 3-5 hours. The reaction mixture was filtered to remove the catalyst and the filtrate was concentrated to dryness. The residue was diluted with 150 mL of ethyl acetate and washed with water and sodium bicarbonate solution. After concentration, the crude product was purified on silica gel eluting with ethyl acetate and 10% methanol in ethyl acetate to give pure (2R,3S)-3-amino-2-hydroxyphenylpropionic acid, 2-trimethylsilylethyl ester as a yellow sticky oil (4.0 g, 70% yield).

**Example-17:**

The amino alcohol from Example-16 (2.2 g, 7.8 mmol) and  $\text{Et}_3\text{N}$  (2.2 mL, 15.6 mmol) were dissolved in 10 mL of THF and cooled with ice water. Benzyl chloroformate (Cbz-Cl) (1.4 mL, 9.36 mmol) was added dropwise to the solution. The resulting white slurry was stirred at room temperature for 2 h. The reaction mixture was diluted with 150 mL of ethyl acetate and washed with water, dilute sulfuric acid and sat'd  $\text{NaCl}$  solution. The crude product was then purified on silica gel eluting with hexane and 10% ethyl acetate in hexane to give the (2R,3S)-3-



-31-

benzyloxycarbonylamino-2-hydroxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.33 g, 41% yield).

**Example-18:**

The (2R,3S)-3-benzyloxycarbonylamino-2-hydroxyphenylpropionic acid, 2-trimethylethylethyl ester (1.33 g, 3.2 mmol) from Example-17 and triethylamine (0.9 mL, 6.4 mmol) were dissolved in 10 mL of THF and cooled with ice water. Benzoyl chloride (0.41 mL, 3.53 mmol) was added dropwise. The mixture was stirred at room temperature overnight and worked up and purified as in Example-14 to give the (2R,3S)-3-benzyloxycarbonylamino-2-benzoyloxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.1g).

**Example-19:**

The (2R,3S)-3-benzyloxycarbonylamino-2-benzoyloxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.1 g) from Example-18 was dissolved in 5 mL of THF and cooled with ice water. A solution of Bu<sub>4</sub>NF in THF (1.0 M, 6mL) was added. The solution was stirred at room temperature for 2-4 h and concentrated to dryness. The residue was dissolved in 100 mL of ethyl acetate and acetified with dilute sulfuric acid and washed with water and sat'd NaCl. After concentration and drying, the (2R,3S)-3-benzyloxycarbonylamino-2-benzoyloxyphenylpropionic acid was obtained as a white foamy solid (0.86 g).

**Example-20:**

A mixture of (2R,3S)-3-benzyloxycarbonylamino-2-benzoyloxyphenylpropionic acid, 2-trimethylsilylethyl ester (1.1 g) (126 mg, 0.3 mmol), 4-pyrrolidinopyridine (22 mg, 0.15 mmol), DCC (68 mg,

-32-

0.32 mmol) and 7-TES-baccatin (70 mg, 0.1 mmol) in 0.4 mL of dry toluene was heated at 50 C for 7 h. The reaction mixture was then cooled and purified on silica gel eluting with hexane and 15% ethyl acetate/hexane to give the (2R,3S)-3-benzylcarbonylamino-2-benzoyloxyphenylpropionic acid, 7-TES-baccatin ester (108 mg).

**Example-21:**


The 7-TES-baccatin ester from Example-20 (50 mg), ammonium formate (0.5 g) and 10% Pd/C (10 mg) were dissolved in methanol (2 mL) and stirred at room temperature for 4-5 h. The catalyst was removed by filtration and the filtrate was concentrated to dryness. The residue was then dissolved in 1 mL of formic acid and stirred at room temperature overnight. The solution was concentrated to dryness and the crude product was purified on silica gel eluting with ethyl acetate to give Taxol (9 mg) identical with natural taxol by HNMR and HPLC.

-33-

## CLAIMS

1. A process for the preparation of taxol and derivatives thereof comprising

- (a) reacting a  $\beta$ -alkoxycarbonylaminophenylpropionic acid of formula




wherein  $R^1$  is  $C_1$  to  $C_{10}$  alkyl,  $C_1$  to  $C_{10}$  alkoxy, phenyl or substituted phenyl;  $R^3$  is hydrogen, loweralkyl, loweralkoxy, di-loweralkylamino or halo; and  $R^4$  is benzyl, t-butyl, allyl, trichloroethyl, or 9-fluorenylmethyl, with a 13-hydroxy taxane to produce a  $\beta$ -alkoxycarbonylaminophenylpropionic ester of said taxane at C-13; and

(b) cleaving the  $\beta$ -alkoxycarbonyl from said  $\beta$ -alkoxycarbonylaminophenylpropionic ester of taxane to produce a  $\beta$ -amido- $\alpha$ -hydroxybenzenepropanoic ester of said taxane.


2. A process according to claim 1 wherein  $R^1$  is phenyl, t-butoxyl or 4-chlorophenyl and  $R^3$  is hydrogen.

3. A process according to claim 1 comprising  
(a) reacting a  $\beta$ -alkoxycarbonylaminophenylpropionic acid of formula


-34-



with a taxane of formula



- 5 to produce an  $\beta$ -alkoxycarbonylaminophenylpropionic ester at C-13 of taxane of formula






-36-

7. A process according to claim 3 wherein said step of cleaving the  $\beta$ -alkoxycarbonyl of said  $\beta$ -alkoxycarbonylamino phenylpropionic ester also cleaves said protecting group for said alcohol, whereby a  
5 2',7-dihydroxy-3'-amidoester is produced in a single reaction.

8. A compound of formula




wherein R<sup>1</sup> is C<sub>1</sub> to C<sub>10</sub> alkyl, C<sub>1</sub> to C<sub>10</sub> alkoxy, phenyl or substituted phenyl; R<sup>3</sup> is hydrogen, loweralkyl, loweralkoxy, di-loweralkylamino or halo; and R<sup>4</sup> is  
5 benzyl, t-butyl, allyl, trichloroethyl, or 9-fluorenylmethyl.

9. A compound according to claim 8 wherein R<sup>1</sup> is phenyl, t-butoxy or 4-chlorophenyl and R<sup>3</sup> is hydrogen.


-37-

10. A compound of formula



wherein  $R^1$  is  $C_1$  to  $C_{10}$  alkyl,  $C_1$  to  $C_{10}$  alkoxy, phenyl or substituted phenyl;  $R^2$  is 1,1,1-trichloroethoxycarbonyl, trialkylsilyl or  
 5 aryldialkylsilyl;  $R^3$  is hydrogen, loweralkyl, loweralkoxy, di-loweralkylamino or halo and  $R^4$  is benzyl, t-butyl, allyl, trichloroethyl, or 9-fluorenylmethyl.

11. A compound of formula



according to claim 10.

-38-

12. A compound according to claim 11 wherein R<sup>2</sup> is trihexylsilyl and R<sup>4</sup> is t-butyl.



# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 96/12666

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 C07D305/14 A61K31/335 C07F7/18 C07C271/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07D A61K C07F C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 336 841 A (RHONE-POULENC SANTE) 11 October 1989 see claim 1	1-12
X	EP 0 336 840 A (CNRS) 11 October 1989 see claim 1	1-12
A	SYNTHESIS, vol. 11, 1993, pages 1162-1176, XP002017074 DONDONI ET AL: "Thiazolyl alpha-Amino Ketones" see page 1170; example 41	8
A	EP 0 569 281 A (BRISTOL-MYERS SQUIBB CO.) 10 November 1993 see claim 1	10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "A" document member of the same patent family

Date of the actual completion of the international search

29 October 1996

Date of mailing of the international search report

17. 12. 96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Gettins, M

# INTERNATIONAL SEARCH REPORT

Internat'l Application No  
PCT/US 96/12666

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 93 21173 A (ABBOTT LAB.) 28 October 1993 see claim 1 ---	10
A	WO 93 18210 A (RHONE-POULENC) 16 September 1993 see claim 1 ---	10
A	EP 0 253 739 A (RHONE-POULENC SANTE) 20 January 1988 see claim 1 -----	1-10

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No  
PCT/US 96/12666

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-336841	11-10-89	FR-A- 2629819	13-10-89
		AU-A- 3242689	12-10-89
		CA-A- 1308417	06-10-92
		ES-T- 2055119	16-08-94
		JP-A- 1305077	08-12-89
		JP-B- 6086441	02-11-94
		US-A- 4924012	08-05-90
-----			
EP-A-336840	11-10-89	FR-A- 2629818	13-10-89
		AU-A- 3251989	12-10-89
		CA-A- 1324611	23-11-93
		DE-D- 68910718	23-12-93
		DE-T- 68910718	31-03-94
		ES-T- 2059794	16-11-94
		JP-A- 1305076	08-12-89
		JP-B- 6086440	02-11-94
		US-A- 4924011	08-05-90
		US-E- RE34277	08-06-93
-----			
EP-A-569281	10-11-93	CA-A- 2095375	07-11-93
		JP-A- 6009600	18-01-94
		US-H- H1487	05-09-95
-----			
WO-A-9321173	28-10-93	AU-B- 672006	19-09-96
		AU-A- 4286393	18-11-93
		CA-A- 2130578	28-10-93
		EP-A- 0639186	22-02-95
		JP-T- 7505887	29-06-95
		US-A- 5352806	04-10-94
		US-A- 5440056	08-08-95
		US-A- 5530020	25-06-96
-----			
WO-A-9318210	16-09-93	FR-A- 2688518	17-09-93
		AT-T- 130053	15-11-95
		CA-A- 2117552	16-09-93
		CZ-A- 9402186	15-02-95
		DE-D- 69300766	14-12-95
		DE-T- 69300766	18-04-96
		EP-A- 0630428	28-12-94
ES-T- 2079982	16-01-96		

# INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat'l Application No

PCT/US 96/12666

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9318210		FI-A- 944190	12-09-94
		HU-A- 68282	03-04-95
		JP-T- 7504461	18-05-95
		NO-A- 943371	12-09-94
		SK-A- 108494	08-02-95
		ZA-A- 9301800	30-09-93
-----			
EP-A-253739	20-01-88	FR-A- 2601676	22-01-88
		AU-B- 591310	30-11-89
		AU-A- 7567887	21-01-88
		CA-A- 1278303	27-12-90
		JP-C- 1878388	07-10-94
		JP-B- 6004607	19-01-94
		JP-A- 63030478	09-02-88
		US-A- 4857653	15-08-89
-----			